Alketa Hamzaj

Arezzo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.

Journal: European urology

Published: May 30, 2022

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 09, 2022

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: February 08, 2022

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Journal: The New England journal of medicine

Published: March 03, 2021

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

Journal: PloS one

Published: April 20, 2018

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

Journal: Future oncology (London, England)

Published: October 06, 2015

Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

Journal: Seminars in oncology

Published: May 13, 2015

Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.

Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.

Journal: Expert review of anticancer therapy

Published: October 30, 2014

Sunitinib therapy in metastatic papillary thyroid cancer.

Sunitinib therapy in metastatic papillary thyroid cancer.

Journal: Tumori

Published: February 08, 2014

Comparing comparators: a look at control arms in kidney cancer studies over the years.

Comparing comparators: a look at control arms in kidney cancer studies over the years.

Journal: British journal of cancer

Published: January 09, 2014

GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer.

GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer.

Journal: Critical reviews in oncology/hematology

Published: February 19, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026